Cancers, Vol. 12, Pages 2961: Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Cancers, Vol. 12, Pages 2961: Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib Cancers doi: 10.3390/cancers12102961 Authors: Katharina Pomej Bernhard Scheiner Dabin Park David Bauer Lorenz Balcar Tobias Meischl Mattias Mandorfer Thomas Reiberger Christian Müller Michael Trauner Matthias Pinter VEGF(R)-targeted therapies are associated with an increased risk of thromboembolism and bleeding, which might be pronounced in patients with increased cardiovascular risk. Nevertheless, sorafenib represents an important treatment option in patients with hepatocellular carcinoma (HCC). We retrospectively investigated the risk of arterial/venous thromboembolic and bleeding events in 252 patients treated with sorafenib for HCC between 05/2006 and 03/2020 at the Medical University of Vienna. Cardiovascular risk was assessed using Framingham score. Eight patients (3.2%) experienced 11 arterial/venous thromboembolic events. Only two patients (0.8%) developed arterial thromboembolism even though cardiovascular risk was low, intermediate, and high in 15 (8.7%), 104 (60%), and 54 (31.2%) of 173 assessable patients. Median overall survival (OS) was shorter in the high risk vs. low/intermediate risk group 7.4 (95% CI: 3.4–11.3) vs. 10.0 (95% CI: 6.8–13.2 months) and independently associated with OS in multivariable analysis HR: 1.53 (95% CI: 1.07–2.19; p = 0.019). Forty-eight (19%) patient...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research